 Greta Wilkening
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urea Cycle Disorders, Inborn | 3 | 2026 | 26 | 1.350 |
Why?
| | Lennox Gastaut Syndrome | 3 | 2022 | 19 | 1.020 |
Why?
| | Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2026 | 7 | 0.950 |
Why?
| | Brain Diseases | 3 | 2022 | 155 | 0.840 |
Why?
| | Neuropsychology | 3 | 2024 | 44 | 0.830 |
Why?
| | Nervous System Diseases | 2 | 2026 | 286 | 0.780 |
Why?
| | Cognition Disorders | 4 | 2026 | 541 | 0.760 |
Why?
| | Hyperammonemia | 3 | 2026 | 17 | 0.650 |
Why?
| | Cognitive Dysfunction | 2 | 2026 | 467 | 0.640 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2012 | 76 | 0.640 |
Why?
| | Memory Disorders | 2 | 2012 | 197 | 0.630 |
Why?
| | Central Nervous System Neoplasms | 2 | 2012 | 177 | 0.590 |
Why?
| | Cognition | 10 | 2024 | 1266 | 0.500 |
Why?
| | Brain Neoplasms | 4 | 2022 | 1329 | 0.500 |
Why?
| | Neurodevelopmental Disorders | 3 | 2026 | 227 | 0.430 |
Why?
| | Child Development | 4 | 2026 | 483 | 0.420 |
Why?
| | Quality of Life | 2 | 2026 | 3204 | 0.410 |
Why?
| | Adolescent | 23 | 2026 | 22529 | 0.410 |
Why?
| | Phenylketonurias | 2 | 2024 | 15 | 0.410 |
Why?
| | Neuropsychological Tests | 8 | 2024 | 1134 | 0.400 |
Why?
| | Medical Oncology | 1 | 2017 | 339 | 0.400 |
Why?
| | Pediatrics | 2 | 2024 | 1121 | 0.390 |
Why?
| | Mass Screening | 1 | 2022 | 1360 | 0.390 |
Why?
| | Child | 32 | 2026 | 22707 | 0.370 |
Why?
| | Nursing Assessment | 1 | 2012 | 53 | 0.360 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2024 | 652 | 0.340 |
Why?
| | Developmental Disabilities | 3 | 2020 | 281 | 0.310 |
Why?
| | Hemophilia A | 2 | 2024 | 148 | 0.300 |
Why?
| | Child, Preschool | 20 | 2026 | 11853 | 0.300 |
Why?
| | Autism Spectrum Disorder | 2 | 2025 | 422 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2025 | 2588 | 0.280 |
Why?
| | Epilepsies, Myoclonic | 2 | 2020 | 59 | 0.270 |
Why?
| | Age of Onset | 3 | 2026 | 555 | 0.270 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5904 | 0.270 |
Why?
| | Humans | 47 | 2026 | 145474 | 0.240 |
Why?
| | Epilepsy | 2 | 2023 | 390 | 0.230 |
Why?
| | Infertility | 1 | 2026 | 61 | 0.230 |
Why?
| | Fertilization in Vitro | 1 | 2026 | 108 | 0.220 |
Why?
| | Young Adult | 9 | 2026 | 14218 | 0.220 |
Why?
| | Electroencephalography | 3 | 2024 | 561 | 0.220 |
Why?
| | Brain | 5 | 2025 | 2947 | 0.210 |
Why?
| | Ammonia | 1 | 2024 | 61 | 0.200 |
Why?
| | Longitudinal Studies | 4 | 2026 | 2953 | 0.200 |
Why?
| | Oxytocin | 1 | 2024 | 51 | 0.200 |
Why?
| | Seizures | 3 | 2024 | 483 | 0.200 |
Why?
| | Survivors | 4 | 2017 | 523 | 0.200 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2024 | 429 | 0.190 |
Why?
| | Male | 27 | 2026 | 72842 | 0.180 |
Why?
| | Female | 30 | 2026 | 78844 | 0.180 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1061 | 0.170 |
Why?
| | Amnesia | 2 | 2012 | 47 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2026 | 497 | 0.170 |
Why?
| | Self Report | 1 | 2026 | 870 | 0.170 |
Why?
| | Infant | 10 | 2024 | 10077 | 0.170 |
Why?
| | Rare Diseases | 1 | 2022 | 116 | 0.170 |
Why?
| | NAV1.2 Voltage-Gated Sodium Channel | 1 | 2020 | 8 | 0.160 |
Why?
| | Hallucinogens | 1 | 2023 | 111 | 0.160 |
Why?
| | Brain Damage, Chronic | 2 | 1999 | 18 | 0.160 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 20 | 0.160 |
Why?
| | Cannabinoids | 1 | 2023 | 184 | 0.160 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 15 | 0.160 |
Why?
| | Cannabidiol | 1 | 2023 | 142 | 0.160 |
Why?
| | Adult | 12 | 2026 | 40777 | 0.150 |
Why?
| | Status Epilepticus | 1 | 2020 | 68 | 0.150 |
Why?
| | Epileptic Syndromes | 1 | 2020 | 98 | 0.150 |
Why?
| | Mothers | 2 | 2023 | 765 | 0.150 |
Why?
| | Self-Injurious Behavior | 1 | 2021 | 141 | 0.150 |
Why?
| | Adaptation, Psychological | 2 | 2024 | 716 | 0.150 |
Why?
| | Cohort Studies | 7 | 2026 | 6013 | 0.140 |
Why?
| | Incidence | 4 | 2019 | 2923 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2026 | 2930 | 0.140 |
Why?
| | Communication | 2 | 2022 | 975 | 0.140 |
Why?
| | Autistic Disorder | 1 | 2021 | 219 | 0.140 |
Why?
| | Frontal Lobe | 1 | 1999 | 160 | 0.140 |
Why?
| | Maternal Exposure | 1 | 2019 | 189 | 0.130 |
Why?
| | Brain Waves | 1 | 2017 | 45 | 0.130 |
Why?
| | Tobacco Smoke Pollution | 1 | 2019 | 227 | 0.130 |
Why?
| | Sleep | 3 | 2020 | 888 | 0.120 |
Why?
| | Benzodiazepines | 1 | 2017 | 168 | 0.120 |
Why?
| | Obesity | 4 | 2025 | 3116 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 826 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2023 | 3922 | 0.120 |
Why?
| | Cannabis | 1 | 2023 | 509 | 0.120 |
Why?
| | Pregnancy | 6 | 2026 | 7202 | 0.110 |
Why?
| | Body Mass Index | 1 | 2024 | 2445 | 0.110 |
Why?
| | Overweight | 1 | 2020 | 614 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 92 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3904 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2023 | 1146 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1097 | 0.110 |
Why?
| | Perception | 1 | 2017 | 378 | 0.100 |
Why?
| | Infant, Newborn | 3 | 2022 | 6447 | 0.100 |
Why?
| | Biomarkers | 2 | 2019 | 4295 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 50 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 6066 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1472 | 0.090 |
Why?
| | Parents | 2 | 2021 | 1403 | 0.090 |
Why?
| | Germinoma | 1 | 2012 | 10 | 0.090 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 74 | 0.090 |
Why?
| | Cerebral Ventricles | 1 | 2012 | 56 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2024 | 17291 | 0.090 |
Why?
| | Pediatric Nursing | 1 | 2012 | 44 | 0.090 |
Why?
| | Radiotherapy, Conformal | 1 | 2012 | 74 | 0.090 |
Why?
| | Oncology Nursing | 1 | 2012 | 35 | 0.090 |
Why?
| | Temporal Lobe | 1 | 2012 | 105 | 0.090 |
Why?
| | Intelligence | 1 | 2012 | 113 | 0.090 |
Why?
| | Aptitude Tests | 1 | 2011 | 4 | 0.090 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2012 | 142 | 0.080 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 198 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 297 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Blood Glucose | 1 | 2019 | 2341 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2512 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 8057 | 0.060 |
Why?
| | Comorbidity | 2 | 2025 | 1661 | 0.060 |
Why?
| | Short Bowel Syndrome | 1 | 2006 | 27 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 699 | 0.060 |
Why?
| | Nutritional Support | 1 | 2006 | 39 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 359 | 0.060 |
Why?
| | Colorado | 4 | 2019 | 4553 | 0.060 |
Why?
| | Neoplasms | 2 | 2012 | 2906 | 0.050 |
Why?
| | Middle Aged | 2 | 2026 | 36215 | 0.050 |
Why?
| | Gray Matter | 1 | 2025 | 92 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2023 | 531 | 0.050 |
Why?
| | Hemophilia B | 1 | 2024 | 65 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1270 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 55 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3747 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 195 | 0.040 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 100 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 412 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2023 | 224 | 0.040 |
Why?
| | Treatment Outcome | 5 | 2023 | 11772 | 0.040 |
Why?
| | Maternal Inheritance | 1 | 2020 | 15 | 0.040 |
Why?
| | Language Development | 1 | 2020 | 59 | 0.040 |
Why?
| | Checklist | 1 | 2021 | 110 | 0.040 |
Why?
| | Motor Skills | 1 | 2020 | 104 | 0.040 |
Why?
| | Wechsler Scales | 1 | 1999 | 61 | 0.040 |
Why?
| | Executive Function | 1 | 2024 | 470 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2105 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 696 | 0.030 |
Why?
| | Inflammation | 1 | 2009 | 2878 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2024 | 867 | 0.030 |
Why?
| | Psychological Tests | 3 | 1983 | 130 | 0.030 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2017 | 22 | 0.030 |
Why?
| | Fasting | 1 | 2019 | 279 | 0.030 |
Why?
| | Behavioral Symptoms | 1 | 1997 | 41 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2019 | 324 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1001 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1581 | 0.030 |
Why?
| | Brain Mapping | 1 | 1999 | 538 | 0.030 |
Why?
| | Craniopharyngioma | 1 | 1997 | 77 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 118 | 0.030 |
Why?
| | Risk Factors | 3 | 2019 | 10885 | 0.030 |
Why?
| | Language | 1 | 2019 | 323 | 0.030 |
Why?
| | Pituitary Neoplasms | 1 | 1997 | 190 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 518 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 642 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5423 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1997 | 0.030 |
Why?
| | Time Factors | 3 | 2012 | 7123 | 0.030 |
Why?
| | Health Status | 1 | 1999 | 832 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3413 | 0.020 |
Why?
| | Prognosis | 2 | 2012 | 4316 | 0.020 |
Why?
| | Organs at Risk | 1 | 2012 | 37 | 0.020 |
Why?
| | Neurocognitive Disorders | 2 | 1982 | 33 | 0.020 |
Why?
| | Organ Sparing Treatments | 1 | 2012 | 37 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2012 | 288 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 149 | 0.020 |
Why?
| | Age Factors | 2 | 2012 | 3342 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 325 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1244 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 852 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1138 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 106 | 0.020 |
Why?
| | United States | 1 | 2026 | 16098 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 422 | 0.020 |
Why?
| | Cisapride | 1 | 2006 | 5 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 4075 | 0.010 |
Why?
| | Gastrointestinal Agents | 1 | 2006 | 65 | 0.010 |
Why?
| | Counseling | 1 | 1989 | 400 | 0.010 |
Why?
| | Dysarthria | 1 | 1984 | 10 | 0.010 |
Why?
| | Speech Disorders | 1 | 1984 | 29 | 0.010 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 115 | 0.010 |
Why?
| | Aluminum | 1 | 1984 | 43 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1997 | 2970 | 0.010 |
Why?
| | Personality Disorders | 1 | 1984 | 78 | 0.010 |
Why?
| | Neurologic Examination | 1 | 1983 | 132 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1984 | 2769 | 0.010 |
Why?
| | Reference Values | 1 | 1983 | 798 | 0.010 |
Why?
| | Antipsychotic Agents | 1 | 1983 | 211 | 0.010 |
Why?
| | Intellectual Disability | 1 | 1981 | 179 | 0.010 |
Why?
| | Schizophrenia | 1 | 1983 | 453 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 167 | 0.010 |
Why?
| | Achievement | 1 | 1997 | 58 | 0.010 |
Why?
| | Social Behavior | 1 | 1997 | 284 | 0.010 |
Why?
| | Tremor | 1 | 1984 | 98 | 0.000 |
Why?
| | Syndrome | 1 | 1984 | 381 | 0.000 |
Why?
| | Phenothiazines | 1 | 1983 | 8 | 0.000 |
Why?
| | Schizophrenic Psychology | 1 | 1983 | 96 | 0.000 |
Why?
| | Aphasia, Wernicke | 1 | 1982 | 2 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1984 | 599 | 0.000 |
Why?
|
|
Wilkening's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|